Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
GRIFOLS THERAPEUTICS LLC	2410 LILLYVALE AVENUE C/O GRIFOLS SHARED SERVICES NORTH AMERICA LOS ANGELES CA 90032-3514

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
• A61P:THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDI....
• C07K:PEPTIDES

• 2008 Application Filing Year
• A61K Class
• 9711 Applications Filed
• 5862 Patents Issued To-Date
• 60.37 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Arora, Vikram	Morrisville, US	8	19
# of filed Patents : 8 Total Citations : 19
Pamarthi, Mohan	Cary, US	3	4
# of filed Patents : 3 Total Citations : 4
Scuderi, Philip	Chapel Hill, US	6	14
# of filed Patents : 6 Total Citations : 14

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 4 Citation Count
• A61K Class

• 10.68 % this patent is cited more than
• 14 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2011/0002,909

METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN

---

Abstract

---

The present invention provides a method for providing alpha-1 antitrypsin (α1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with α1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of α1-AT to the subject. Also provided is a composition and article of manufacture comprising α1-AT, in particular a formulation suitable for subcutaneous administration of α1-AT.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.